UY33486A - Derivados de tetrahidro-pirido-pirimidina - Google Patents

Derivados de tetrahidro-pirido-pirimidina

Info

Publication number
UY33486A
UY33486A UY0001033486A UY33486A UY33486A UY 33486 A UY33486 A UY 33486A UY 0001033486 A UY0001033486 A UY 0001033486A UY 33486 A UY33486 A UY 33486A UY 33486 A UY33486 A UY 33486A
Authority
UY
Uruguay
Prior art keywords
tetrahydro
pyrid
pyrimidine derivatives
mediated
disorder
Prior art date
Application number
UY0001033486A
Other languages
English (en)
Inventor
Nigel Graham Cooke
Paulo Fernandes Gomes Dos Santos
Graveleau Nadege
Hebach Christina
Klemens Hoegenauer
Hollingworth Gregory
Alexander Baxter Smith
Soldermann Nicolas
Stowasser Frank
Strang Ross
Tufilli Nicola
Anette Von Matt
Wolf Romain
Frederic Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33486A publication Critical patent/UY33486A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La invención se refiere a derivados de tetrahidro-piridopirimidina sustituidos de la fórmula (I) en donde Y, R1, R2 y m son como se definen en la descripción. Estos compuestos son adecuados para el tratamiento de un trastorno o de una enfermedad que sea mediada por la actividad de las enzimas de PI3K.
UY0001033486A 2010-07-06 2011-07-06 Derivados de tetrahidro-pirido-pirimidina UY33486A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36158910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
UY33486A true UY33486A (es) 2012-02-29

Family

ID=44532774

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033486A UY33486A (es) 2010-07-06 2011-07-06 Derivados de tetrahidro-pirido-pirimidina

Country Status (39)

Country Link
US (9) US8653092B2 (es)
EP (1) EP2590974B1 (es)
JP (1) JP5770842B2 (es)
KR (1) KR101560066B1 (es)
CN (1) CN102971317B (es)
AR (3) AR084970A1 (es)
AU (1) AU2011275777C1 (es)
BR (1) BR112013000275B1 (es)
CA (1) CA2802132C (es)
CL (1) CL2013000033A1 (es)
CO (1) CO6670566A2 (es)
CR (1) CR20130004A (es)
DK (1) DK2590974T3 (es)
DO (1) DOP2013000027A (es)
EA (1) EA024123B1 (es)
EC (1) ECSP13012420A (es)
ES (1) ES2494718T3 (es)
GT (1) GT201300009A (es)
HK (1) HK1179966A1 (es)
HR (1) HRP20140778T1 (es)
IL (1) IL223795A (es)
JO (1) JO2939B1 (es)
MA (1) MA34361B1 (es)
MX (1) MX2012015088A (es)
MY (1) MY166026A (es)
NI (1) NI201300002A (es)
NZ (1) NZ604302A (es)
PE (1) PE20130650A1 (es)
PL (1) PL2590974T3 (es)
PT (1) PT2590974E (es)
RS (1) RS53490B1 (es)
SG (1) SG186187A1 (es)
SI (1) SI2590974T1 (es)
TN (1) TN2012000578A1 (es)
TW (1) TWI534145B (es)
UA (1) UA112517C2 (es)
UY (1) UY33486A (es)
WO (1) WO2012004299A1 (es)
ZA (1) ZA201209117B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
MX2013015001A (es) 2011-06-27 2014-03-31 Novartis Ag Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
US9949979B2 (en) * 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
AU2013347539B2 (en) * 2012-11-16 2017-06-15 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015162584A1 (en) 2014-04-24 2015-10-29 Novartis Ag Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
JP6462155B2 (ja) * 2015-05-04 2019-01-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
PL3413894T3 (pl) 2016-02-10 2020-10-05 Novartis Ag Zastosowanie inhibitorów aktywności lub czynności PI3K do leczenia pierwotnego zespołu Sjögrena
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
PT3651768T (pt) 2017-07-13 2024-03-20 Univ Texas Inibidores heterocíclicos da atr cinase
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
CN114315826B (zh) * 2021-11-30 2023-05-16 西安交通大学 一种吡啶并嘧啶类化合物及其应用
KR20230160977A (ko) 2022-05-17 2023-11-27 에이치앤오바이오시스(주) 항암 치료에 사용되는 5종 이상의 생약 추출물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5300645A (en) 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
ATE308527T1 (de) 1996-06-24 2005-11-15 Pfizer Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002221810B2 (en) 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
AU2003292437A1 (en) * 2002-12-27 2004-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP5283336B2 (ja) 2004-01-12 2013-09-04 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド 選択的キナーゼ阻害剤
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
RU2364596C2 (ru) 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7745451B2 (en) * 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2566387T3 (es) * 2007-04-02 2016-04-12 Evotec Ag Compuestos heterocíclicos condensados de pirid-2-ilo, y composiciones y usos de los mismos
CA2682692A1 (en) * 2007-04-17 2008-10-30 Renovis, Inc. 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2707047C (en) 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2010033495A2 (en) 2008-09-16 2010-03-25 Schering Corporation Functionally selective azanitrile alpha2c adrenoreceptor agonists
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
JP2010105951A (ja) 2008-10-29 2010-05-13 Dainippon Sumitomo Pharma Co Ltd ６−アルキル置換テトラヒドロピリド［４，３−ｄ］ピリミジン誘導体
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2010120991A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
EP2434885B1 (en) 2009-05-27 2014-03-26 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
EP2521553A4 (en) 2010-01-06 2013-08-28 Errico Joseph P METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K

Also Published As

Publication number Publication date
CL2013000033A1 (es) 2013-05-10
US20200392132A1 (en) 2020-12-17
KR20130041068A (ko) 2013-04-24
PE20130650A1 (es) 2013-06-15
AR118919A2 (es) 2021-11-10
SI2590974T1 (sl) 2014-08-29
HK1179966A1 (en) 2013-10-11
US20170022199A1 (en) 2017-01-26
US9499536B2 (en) 2016-11-22
CA2802132C (en) 2019-02-26
ZA201209117B (en) 2013-09-25
PT2590974E (pt) 2014-09-01
AU2011275777C1 (en) 2015-02-05
UA112517C2 (uk) 2016-09-26
US20170267678A1 (en) 2017-09-21
US20180265509A1 (en) 2018-09-20
AR115927A2 (es) 2021-03-10
EA201291317A1 (ru) 2013-05-30
MX2012015088A (es) 2013-02-12
CN102971317B (zh) 2016-01-20
CA2802132A1 (en) 2012-01-12
AU2011275777A1 (en) 2012-12-20
MA34361B1 (fr) 2013-07-03
DOP2013000027A (es) 2013-09-30
BR112013000275B1 (pt) 2020-12-01
AU2011275777B2 (en) 2014-07-31
PL2590974T3 (pl) 2014-10-31
US8653092B2 (en) 2014-02-18
HRP20140778T1 (hr) 2014-09-12
EP2590974A1 (en) 2013-05-15
US20140128370A1 (en) 2014-05-08
BR112013000275A2 (pt) 2016-06-14
EA024123B1 (ru) 2016-08-31
JP2013535411A (ja) 2013-09-12
EP2590974B1 (en) 2014-05-21
US20120065183A1 (en) 2012-03-15
CN102971317A (zh) 2013-03-13
ECSP13012420A (es) 2013-03-28
ES2494718T3 (es) 2014-09-16
CR20130004A (es) 2013-04-17
US20220267318A1 (en) 2022-08-25
MY166026A (en) 2018-05-21
TW201206930A (en) 2012-02-16
US20190218217A1 (en) 2019-07-18
TN2012000578A1 (en) 2014-04-01
IL223795A (en) 2015-11-30
JO2939B1 (en) 2016-03-15
AR084970A1 (es) 2013-07-24
NZ604302A (en) 2014-11-28
JP5770842B2 (ja) 2015-08-26
CO6670566A2 (es) 2013-05-15
WO2012004299A1 (en) 2012-01-12
DK2590974T3 (da) 2014-07-28
RS53490B1 (en) 2015-02-27
KR101560066B1 (ko) 2015-10-13
NI201300002A (es) 2013-04-15
SG186187A1 (en) 2013-01-30
TWI534145B (zh) 2016-05-21
GT201300009A (es) 2015-06-02
US20190040061A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2011000260A (es) Pirimidinas fusionadas
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CO6761389A2 (es) Inhibidores de nampt y rock
CR20150370A (es) Compuestos antivirales
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
EA201201648A1 (ru) Стимуляторы sgc
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
UY35257A (es) Picolinamidas macrocíclicas como fungicidas, composiciones y metodos para el control de enfermedades vegetales
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
DOP2014000253A (es) Inhibidores del nampt
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
BR112013012858A2 (pt) anticorpos que se ligam a pectina acetilesterase de notum
EA201590656A1 (ru) Азаиндолины
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
CY1115457T1 (el) Παραγωγα τετραϋδρο-πυριδο-πυριμιδινης
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20210916